Hospital
Vaughan Regional Medical Center LLC
Vaughan Regional Medical Center LLC was paid $8.15M by Medicaid between Jan 2018 and Dec 2024, across 131 billing codes. Its largest line is 99285, emergency room visit (most serious) — 37% of everything it billed.
33Billing provider infoVAUGHAN REGIONAL MEDICAL CENTER LLC
SELMA, AL 36701
SELMA, AL 36701
33aNPI1871655993assigned 12/14/2006
33bProvider typeRural Acute Care Hospital
28Total paid$8.15M
24GClaims299,699
24DCodes billed131
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Alabama
Rank by total paid#1 of 11
Median peer was paid$1.34M
This provider vs. median6.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TEAGUE, KATHY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,814 | $1.29M | |
| 2019 | 56,024 | $1.36M | |
| 2020 | 34,696 | $980K | |
| 2021 | 41,054 | $1.16M | |
| 2022 | 42,900 | $1.22M | |
| 2023 | 44,288 | $1.44M | |
| 2024incomplete | 18,923 | $704K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 37% | 15,143 | 12,255 | $3.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 17,237 | 15,045 | $976K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.2% | 18,539 | 16,990 | $669K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 7.8% | 3,262 | 2,960 | $635K |
| 76376 | 6.1% | 9,456 | 7,646 | $494K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 32,068 | 26,232 | $233K |
| 80053 | Comprehensive metabolic panel | 2.4% | 23,015 | 18,690 | $197K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 4,274 | 3,640 | $180K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 4,161 | 3,814 | $159K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,271 | 1,901 | $147K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 2,890 | 2,676 | $109K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.3% | 3,862 | 3,581 | $104K |
119 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 2,769 | $104K |
| 87486 | 1.2% | 3,121 | $94K | |
| 87581 | 1.2% | 3,120 | $94K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.1% | 3,121 | $94K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 1,926 | $87K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,413 | $74K |
| 81001 | <1% | 17,590 | $59K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,979 | $54K |
| 84703 | <1% | 8,992 | $51K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,938 | $41K |
| 87430 | <1% | 2,012 | $31K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,300 | $29K |
| 84484 | <1% | 4,440 | $25K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,545 | $23K |
| 86762 | <1% | 1,086 | $22K | |
| 86592 | <1% | 3,512 | $20K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,032 | $19K |
| 85610 | <1% | 5,367 | $17K | |
| 83020 | <1% | 926 | $16K | |
| 87340 | <1% | 1,092 | $15K | |
| 82105 | <1% | 702 | $15K | |
| 80061 | Lipid panel | <1% | 1,407 | $14K |
| 86850 | <1% | 1,837 | $12K | |
| 83735 | <1% | 2,456 | $11K | |
| 83690 | <1% | 2,415 | $11K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 105 | $11K |
| 83655 | <1% | 709 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,273 | $10K |
| 83880 | <1% | 540 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 499 | $10K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 264 | $9K |
| 85730 | <1% | 5,363 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,601 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,127 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 612 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 41 | $6K |
| 85018 | <1% | 1,952 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 77 | $6K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 167 | $6K |
| 85014 | <1% | 1,746 | $6K | |
| 82607 | <1% | 504 | $5K | |
| 86900 | <1% | 1,628 | $5K | |
| 86901 | <1% | 1,627 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,166 | $5K |
| 0012A | <1% | 165 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 346 | $4K |
| 82947 | <1% | 935 | $4K | |
| 0011A | <1% | 205 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 208 | $3K |
| 86756 | <1% | 164 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 687 | $3K |
| 85379 | <1% | 407 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 495 | $2K |
| 82746 | <1% | 352 | $2K | |
| 73562 | <1% | 118 | $2K | |
| 87040 | <1% | 252 | $2K | |
| 74022 | <1% | 165 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,595 | $2K |
| 83550 | <1% | 341 | $2K | |
| 82728 | <1% | 328 | $2K | |
| 85027 | <1% | 351 | $2K | |
| 82805 | <1% | 86 | $2K | |
| 87400 | <1% | 362 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 40 | $1K |
| 83540 | <1% | 341 | $1K | |
| 76818 | <1% | 26 | $1K | |
| 83605 | <1% | 147 | $994.61 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 18 | $864.81 |
| 87070 | <1% | 82 | $856.10 | |
| 86140 | <1% | 455 | $806.89 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 219 | $784.98 |
| 82043 | <1% | 183 | $573.90 | |
| 76801 | <1% | 28 | $566.16 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $393.26 |
| 82247 | <1% | 88 | $392.85 | |
| 82248 | <1% | 115 | $370.80 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 24 | $323.52 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 32 | $241.08 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 41 | $226.56 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,844 | $204.64 |
| 72170 | <1% | 12 | $184.68 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 166 | $182.14 |
| 80076 | <1% | 34 | $167.20 | |
| 85007 | <1% | 31 | $164.64 | |
| 84702 | <1% | 16 | $156.24 | |
| 72110 | <1% | 12 | $139.12 | |
| 87186 | <1% | 36 | $131.43 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 276 | $117.64 |
| 87077 | <1% | 35 | $116.74 | |
| 84439 | <1% | 18 | $100.90 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 87 | $92.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 139 | $72.25 |
| 80069 | <1% | 15 | $71.82 | |
| 85660 | <1% | 13 | $64.44 | |
| 82570 | <1% | 14 | $53.76 | |
| 81003 | <1% | 14 | $47.74 | |
| 82150 | <1% | 27 | $40.35 | |
| 84156 | <1% | 14 | $35.92 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,826 | $33.55 |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,382 | $24.33 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 15 | $10.30 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 41 | $8.85 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 22 | $6.88 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 28 | $5.84 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 37 | $1.98 |
| J2704 | Injection, propofol, 10 mg | <1% | 81 | $0.58 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 50 | $0.28 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,727 | $0.19 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 1,306 | $0.00 |
| 81025 | 0% | 36 | $0.00 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 0% | 275 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 36 | $0.00 |
| A9270 | Non-covered item or service | 0% | 674 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 150 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 174 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 27 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 126 | $0.00 |
| 91301 | 0% | 171 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTEAGUE, KATHY (ASSISTANT VICE PRESIDENT, SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Rchp-Wilmington, LLC | Wilmington, OH | $13.53M |
| Providence Hospital, LLC | Columbia, SC | $12.68M |
| Kershaw Hospital LLC | Camden, SC | $7.93M |
| Bolivar Physician Practices LLC | Cleveland, MS | $3.05M |
| Wilmington Physicians Group LLC | Wilmington, OH | $3.04M |
| Phc-Morgan City LP | Morgan City, LA | $2.37M |
| Community Hospital of Andalusia LLC | Andalusia, AL | $2.27M |
| Vaughan Regional Medical Center LLC | Marion, AL | $2.15M |
| PRHC Ennis LP | Ennis, TX | $1.81M |
| Andalusia Physician Practices LLC | Andalusia, AL | $847K |
| Meadowview Physician Practice LLC | Maysville, KY | $783K |
| Logan Physician Practice LLC | Auburn, KY | $458K |
| Logan Physician Practice LLC | Russellville, KY | $317K |
| Kentucky Mso LLC | Georgetown, KY | $248K |
| Rchp-Wilmington, LLC | Wilmington, OH | $165K |
| Meadowview Physician Practice LLC | Maysville, KY | $140K |
| Amg-Southern Tennessee LLC | Monteagle, TN | $136K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $135K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $57K |
| Kershaw Hospital LLC | Lugoff, SC | $49K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.